Isis Reports That ISIS 301012 Is Well Tolerated In Patients Treated For Five Or More Months
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced the first safety results from its ongoing Phase 2 open-label extension (OLE) study of ISIS 301012 in patients with familial hypercholesterolemia (FH) on stable maximally tolerated lipid-lowering therapies. [click link for full article]
More: continued here